Skip to main content
. 2022 Apr 8;8:176. doi: 10.1038/s41420-022-00987-6

Fig. 4. PDCD6 K90 mutation promotes tumor apoptosis in vitro and in vivo.

Fig. 4

A The proliferation of MS751 cells with WT rPDCD6 or rPDCD6 K90R mutation was examined by CCK8 assay under normal or glucose deprivation. *P < 0.05, ##P < 0.01. B Cell apoptosis of MS751 cells with WT rPDCD6 or rPDCD6 K90R mutation was analyzed by Annexin V assay followed by flow cytometry (Top panel). Quantitative results were shown in bottom panel. Error bar mean ± s.d. ***P < 0.001, *P < 0.05. C MS751 cells with WT rPDCD6 or rPDCD6 K90R mutation were analyzed with immunoblotting with the indicated antibodies under normal or glucose deprivation. D MS751 cells with depleted PDCD6 and reconstituted expression of WT rPDCD6 or rPDCD6 K90R were treated with CHX (10 μg/ml) for 8 h under glucose deprivation. The below panel showed relative protein amounts of different groups. Error bar mean ± s.d. of triplicate experiments. ***P < 0.001, **P < 0.01. E K90R mutation inhibits xenograft tumor growth. Subcutaneous xenograft experiment was performed in nude mice using MS751 rPDCD6 WT and rPDCD6 K90R stable cell lines. Diameters of tumors were measured and tumor volumes were calculated. **P < 0.01.